David Sterman has worked as an investment analyst for nearly two decades. He started his Wall Street career in equity research at Smith Barney, culminating in a position as Senior Analyst covering European banks. While at Smith Barney, he learned of all the tricks used by Wall Street to steer the best advice to their top clients and their own trading desk.
David has also served as Managing Editor at TheStreet.com and Director of Research at Individual Investor. In addition, David worked as Director of Research for Jesup & Lamont Securities. David has made numerous media appearances over the years, primarily on CNBC and Bloomberg TV, and has a master's degree in management from Georgia Tech.
David Stermanon
Analyst Articles
When you voluntarily cease doing business with your biggest customer, you best have a good explanation. If not, then investors will think you’re nuts — and dump your stock. But car battery maker Exide Technologies (Nasdaq: XIDE) had a good excuse. The company’s biggest customer, Wal-Mart (NYSE: WMT) made life… Read More
Many of you invest right alongside me and my $100,000 Real-Money Portfolio. And since your money is at stake here, along with the $100,000 in real money that StreetAuthority has given me to invest, I’m constantly monitoring my holdings. As some of you may have noticed, there’s… Read More
Investors focused on larger companies saw their ups and downs in 2011. Rather than focus on the usual suspects, perhaps they should have been focused on antimony. It’s an obscure — and toxic — element that has some appealing industrial applications such as flame retardants and in solder and ball… Read More
As an income investor, my favorite combination is a high-yielding stock poised for above-average dividend growth. Fortunately, these stocks aren’t that difficult to find if you know what to look for. I find the best dividend growth prospects are companies with… Read More
Unless you frequent our website, StreetAuthority.com, I’d guess you’ve never heard of David Sterman. That’s about to change… Dave has worked as an investment analyst for nearly two decades. He started his career in equity research at Smith Barney, culminating in a position as… Read More
The appeal of finding the right biotech stock is self-evident. If you get it right, and a cutting-edge biotech scores a major win with a breakthrough drug treatment, then you can score huge gains. Last month, I reviewed my performance over the course of 2011 in hopes… Read More
Finally, the stock market and economy are doing noticeably better. Perhaps the most welcome sign is unemployment, which has gradually worked its way down to 8.5% from a recession high of… Read More
Depending on your area of focus, earnings season is either well underway or hasn’t even started yet. Many large-cap stocks have weighed in, and almost half of the S&P 500 will have delivered quarterly results by the end of this week. Most… Read More
We humans are pretty predictable. We live our lives in certain patterns and according to certain preferences. There was a time when no one knew what those preferences were. The guy taking my order at a restaurant might remember I like Diet Coke, or the mechanic might… Read More
Investing in any recent initial public offering (IPO) carries one obvious risk: You may be buying as insiders and underwriters are getting set to sell. By federal law, these folks are “locked up,” prevented from selling stock for 180 days after the… Read More
